Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119160 | 0.86 | KDM4E (0.54) | KDM4EKMT2AFDPSMGAMMMP2 | |
| SCHEMBL2117610 | 0.86 | KDM4E (0.54) | KDM4EKMT2AFDPSMGAMMMP2 | |
| SCHEMBL13689608 | 0.86 | PIM1 (0.59) | KDM4EKMT2AFDPSMEN1ALDH1A1 | |
| SCHEMBL2120585 | 0.85 | KDM4E (0.53) | KDM4EKMT2AFDPSMGAMMMP2 | |
| SCHEMBL7036195 | 0.84 | KDM4E (0.62) | KDM4EKMT2AMGAMMMP2MEN1 | |
| SCHEMBL2118893 | 0.84 | FDPS (0.52) | KDM4EKMT2AFDPSMGAMMMP2 | |
| SCHEMBL2118027 | 0.84 | FDPS (0.57) | KDM4EKMT2AFDPSMGAMMMP2 | |
| SCHEMBL2118134 | 0.84 | FDPS (0.52) | KDM4EKMT2AFDPSMGAMMMP2 | |
| Lithium SCHEMBL2116737 | 0.83 | FDPS (0.51) | KDM4EKMT2AFDPSMGAMMMP2 | |
| SCHEMBL2116734 | 0.83 | FDPS (0.51) | KDM4EKMT2AFDPSMGAMMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | claimed |
| CN-101959865-A | Quinolines as farnesyl pyrophosphate synthase inhibitor | NOVARTIS AG | 2011-01-26 | — | — | CN | claimed |
| EP-2250152-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | Novartis AG (CH) | 2010-11-17 | — | — | EP | claimed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | disclosed |
| CN-101959865-A | Quinolines as farnesyl pyrophosphate synthase inhibitor | NOVARTIS AG | 2011-01-26 | — | — | CN | disclosed |
| EP-2250152-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | FDPS, GGPS1, CTPS1 | KDM4E 2805/4885KMT2A 3963/4885FDPS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.